Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2017, Article ID 2739539, 9 pages
https://doi.org/10.1155/2017/2739539
Research Article

Febuxostat Attenuates Renal Damage besides Exerting Hypouricemic Effect in Streptozotocin-Induced Diabetic Rats

1Department of Endocrinology, Guangzhou Red Cross Hospital, Medical School of Jinan University, No. 396 Tong Fu Zhong Road, Guangzhou, China
2Guangzhou Institute of Disease-Oriented Nutritional Research, Guangzhou Red Cross Hospital, Medical School of Jinan University, No. 396 Tong Fu Zhong Road, Guangzhou, China
3Department of Nephrology, Guangzhou Red Cross Hospital, Medical School of Jinan University, No. 396 Tong Fu Zhong Road, Guangzhou, China
4Southern Medical University, No. 1023-1063 Southern Sha Tai Road, Guangzhou, China

Correspondence should be addressed to Jianmin Ran; moc.nsm@mjnar

Received 3 March 2017; Revised 20 March 2017; Accepted 27 March 2017; Published 19 April 2017

Academic Editor: Franca Anglani

Copyright © 2017 Jianmin Ran et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Afkarian, L. R. Zelnick, Y. N. Hall et al., “Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014,” The Journal of the American Medical Association, vol. 316, no. 6, pp. 602–610, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Helou, A. Dwyer, M. Shaha, and A. Zanchi, “Multidisciplinary management of diabetic kidney disease: a systematic review and meta-analysis,” JBI Database of Systematic Reviews and Implementation Reports, vol. 14, pp. 169–207, 2016. View at Google Scholar
  3. P. Hovind, P. Rossing, L. Tarnow, R. J. Johnson, and H. H. Parving, “Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study,” Diabetes, vol. 58, pp. 1668–1671, 2009. View at Google Scholar
  4. Y. Hayashino, S. Okamura, S. Tsujii, and H. Ishii, “Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 10)],” Acta Diabetologica, vol. 53, no. 4, pp. 599–607, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. Y.-H. Chang, C.-C. Lei, K.-C. Lin, D.-M. Chang, C.-H. Hsieh, and Y.-J. Lee, “Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus—a 4.6-year cohort study,” Diabetes/Metabolism Research and Reviews, vol. 32, pp. 557–564, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Mende, “Management of chronic kidney disease: the relationship between serum uric acid and development of nephropathy,” Advances in Therapy, vol. 32, no. 12, pp. 1177–1191, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Li, H. Yang, Y. Guo et al., “Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis,” Scientific Reports, vol. 6, no. 1, Article ID 33082, 2016. View at Publisher · View at Google Scholar
  8. T. Nakamura, T. Murase, M. Nampei et al., “Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice,” European Journal of Pharmacology, vol. 780, pp. 224–231, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Komers, B. Xu, J. Schneider, and T. T. Oyama, “Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes,” British Journal of Pharmacology, vol. 173, pp. 2573–2588, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. J. T. Kratzer, M. A. Lanaspa, M. N. Murphy et al., “Evolutionary history and metabolic insights of ancient mammalian uricases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 10, pp. 3763–3768, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Ran, J. Ma, Y. Liu, R. Tan, H. Liu, and G. Lao, “Low protein diet inhibits uric acid synthesis and attenuates renal damage in streptozotocin-induced diabetic rats,” Journal of Diabetes Research, vol. 2014, Article ID 287536, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Wang, Y. Pan, Q.-Y. Zhang, F.-M. Wang, and L.-D. Kong, “Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation,” PLoS ONE, vol. 7, no. 6, Article ID e38285, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. D. S. Ibrahim and M. A. E. Abd El-Maksoud, “Effect of strawberry (Fragaria × ananassa) leaf extract on diabetic nephropathy in rats,” International Journal of Experimental Pathology, vol. 96, no. 2, pp. 87–93, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. L. P. Peters and R. W. Teel, “Effect of high sucrose diet on liver enzyme content and activity and aflatoxin B1-induced mutagenesis,” In Vivo, vol. 17, no. 2, pp. 205–210, 2003. View at Google Scholar · View at Scopus
  15. Y. Jin and T. Manabe, “High-efficiency protein extraction from polyacrylamide gels for molecular mass measurement by matrix-assisted laser desorption/ionization-time of flight-mass spectrometry,” Electrophoresis, vol. 26, no. 6, pp. 1019–1028, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Hovind, P. Rossing, R. J. Johnson, and H.-H. Parving, “Serum uric acid as a new player in the development of diabetic nephropathy,” Journal of Renal Nutrition, vol. 21, no. 1, pp. 124–127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Dousdampanis, K. Trigka, C. G. Musso, and C. Fourtounas, “Hyperuricemia and chronic kidney disease: an enigma yet to be solved,” Renal Failure, vol. 36, no. 9, pp. 1351–1359, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. S. S. Roscioni, H. J. L. Heerspink, and D. De Zeeuw, “The effect of RAAS blockade on the progression of diabetic nephropathy,” Nature Reviews Nephrology, vol. 10, no. 2, pp. 77–87, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Eräranta, V. Kurra, A. M. Tahvanainen et al., “Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency,” Journal of Hypertension, vol. 26, no. 8, pp. 1661–1668, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. D. B. Corry, P. Eslami, K. Yamamoto, M. D. Nyby, H. Makino, and M. L. Tuck, “Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system,” Journal of Hypertension, vol. 26, no. 2, pp. 269–275, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. V. Filiopoulos, D. Hadjiyannakos, and D. Vlassopoulos, “New insights into uric acid effects on the progression and prognosis of chronic kidney disease,” Renal Failure, vol. 34, no. 4, pp. 510–520, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Wada and H. Makino, “Inflammation and the pathogenesis of diabetic nephropathy,” Clinical Science, vol. 124, no. 3, pp. 139–152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Qiu and L. Tang, “Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy,” Pharmacological Research, vol. 114, pp. 251–264, 2016. View at Publisher · View at Google Scholar
  24. T. T. Braga, M. F. Forni, M. Correa-Costa et al., “Soluble uric acid activates the NLRP3 inflammasome,” Scientific Reports, vol. 7, article 39884, 2017. View at Publisher · View at Google Scholar
  25. S.-M. Kim, S.-H. Lee, Y.-G. Kim et al., “Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy,” American Journal of Physiology—Renal Physiology, vol. 308, no. 9, pp. F993–F1003, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Kosugi, T. Nakayama, M. Heinig et al., “Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice,” American Journal of Physiology—Renal Physiology, vol. 297, no. 2, pp. F481–F488, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Kushiyama, K. Tanaka, S. Hara, and S. Kawazu, “Linking uric acid metabolism to diabetic complications,” World Journal of Diabetes, vol. 5, no. 6, pp. 787–795, 2014. View at Publisher · View at Google Scholar
  28. H.-J. Lee, K. H. Jeong, Y. G. Kim et al., “Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model,” American Journal of Nephrology, vol. 40, no. 1, pp. 56–63, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. D. M. Maahs, L. Caramori, D. Z. I. Cherney et al., “Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study,” Current Diabetes Reports, vol. 13, no. 4, pp. 550–559, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Momeni, S. Shahidi, S. Seirafian, S. Taheri, and S. Kheiri, “Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients,” Iranian Journal of Kidney Diseases, vol. 4, no. 2, pp. 128–132, 2010. View at Google Scholar · View at Scopus
  31. P. Liu, Y. Chen, B. Wang, F. Zhang, D. Wang, and Y. Wang, “Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study,” Clinical Endocrinology, vol. 83, no. 4, pp. 475–482, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Krishnamurthy, N. Rani, S. Bharti et al., “Febuxostat ameliorates doxorubicin-induced cardiotoxicity in rats,” Chemico-Biological Interactions, vol. 237, pp. 96–103, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. L. G. Sánchez-Lozada, E. Tapia, P. Bautista-García et al., “Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome,” American Journal of Physiology—Renal Physiology, vol. 294, no. 4, pp. F710–F718, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Osmundsen, B. Brodal, and R. Hovik, “A luminometric assay for peroxisomal β-oxidation. Effects of fasting and streptozotocin-diabetes on peroxisomal β-oxidation,” Biochemical Journal, vol. 260, no. 1, pp. 215–220, 1989. View at Publisher · View at Google Scholar · View at Scopus
  35. I. J. Kim, Y. K. Kim, S. M. Son, K. W. Hong, and C. D. Kim, “Enhanced vascular production of superoxide in OLETF rat after the onset of hyperglycemia,” Diabetes Research and Clinical Practice, vol. 60, no. 1, pp. 11–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Banerjee and P. Vats, “Reactive metabolites and antioxidant gene polymorphisms in Type 2 diabetes mellitus,” Redox Biology, vol. 2, no. 1, pp. 170–177, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. L. G. Sánchez-Lozada, E. Tapia, V. Soto et al., “Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia,” Nephrology Dialysis Transplantation, vol. 23, no. 4, pp. 1179–1185, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. S. A. Fathallah-Shaykh and M. T. Cramer, “Uric acid and the kidney,” Pediatric Nephrology, vol. 29, no. 6, pp. 999–1008, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Grabowski, R. Khosravan, J.-T. Wu, L. Vernillet, and C. Lademacher, “Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase,” British Journal of Clinical Pharmacology, vol. 70, no. 1, pp. 57–64, 2010. View at Publisher · View at Google Scholar · View at Scopus